TABLE 3.
Uni‐ and multivariate analyses of overall survival (OS) in each tumor location in DNA mismatch repair proficiency
| OS | ||||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Right‐sided | ||||
| Sex (M vs F) | 1.4708 (0.3868‐6.9864) | .5792 | — | — |
| Age, y (≤70 vs 70<) | 0.5468 (0.0792‐2.4145) | .4446 | — | — |
| Tumor depth (T1‐2 vs T3‐4) | Not estimated | .1556 | — | — |
| Lymph node metastasis (− vs +) | 0.5803 (0.1414‐2.8439) | .4705 | — | — |
| Tumor differentiation (well/mod vs others) | 0.9602 (0.1691‐18.012) | .9700 | — | — |
| Lymphatic invasion (− vs +) | 1.8034 (0.4408‐8.8175) | .4125 | — | — |
| Venous invasion (− vs +) | 0.4018 (0.0215‐2.2668) | .3418 | — | — |
| Perineural invasion (− vs +) | 0.3743 (0.0858‐2.5630) | .2726 | — | — |
| HLA class I (low vs high) | 0.7919 (0.1958‐2.9964) | .7275 | — | — |
| HLA class II (low vs high) | 1.3584 (0.3589‐5.4955) | .6471 | — | — |
| tPD‐L1 (low vs high) | 0.8374 (0.2068‐3.1734) | .7913 | — | — |
| sPD‐L1 (low vs high) | 1.3198 (0.3102‐5.6158) | .6966 | — | — |
| PD‐1 (low vs high) | 1.4554 (0.3550‐7.1293) | .6043 | — | — |
| CTLA‐4 (low vs high) | 4.2365 (1.0184‐28.519) | .0470* | 3.4053 (0.7683‐23.727) | .1105 |
| CD3 (low vs high) | 1.1376 (0.2685‐4.8206) | .8556 | — | — |
| CD4 (low vs high) | 1.3014 (0.3060‐5.5363) | .7112 | — | — |
| CD8 (low vs high) | 1.0485 (0.2473‐4.4458) | .9467 | — | — |
| TIA‐1 (low vs high) | 1.5232 (0.4013‐6.1790) | .5303 | — | — |
| T‐bet (low vs high) | 1.7270 (0.4546‐7.0084) | .4155 | — | — |
| GATA3 (low vs high) | 3.6282 (0.8704‐24.463) | .0787 | — | — |
| Foxp3 (low vs high) | 4.2911 (1.0283‐28.943) | .0454* | 3.4420 (0.7787‐23.947) | .1066 |
| RorγT (low vs high) | 1.5860 (0.4180‐6.4309) | .4914 | — | — |
| CD163 (low vs high) | 1.4638 (0.3854‐5.9416) | .5701 | — | — |
| Left‐sided | ||||
| Sex (M vs F) | 0.8082 (0.3679‐1.9001) | .6104 | — | — |
| Age, y (≤70 vs 70<) | 0.5784 (0.2648‐1.2825) | .1739 | — | — |
| Tumor depth (T1‐2 vs T3‐4) | 0.3058 (0.0171‐1.4537) | .1614 | — | — |
| Lymph node metastasis (N− vs N+) | 0.3339 (0.1303‐0.7605) | .0082* | 0.6190 (0.2189‐1.6265) | .3344 |
| Tumor differentiation (well/mod vs others) | 0.1891 (0.0800‐0.4964) | .0014* | 0.2895 (0.1018‐0.8644) | .0274* |
| Lymphatic invasion (− vs +) | 0.2622 (0.0873‐0.6459) | .0027* | 0.3336 (0.1037‐0.9127) | .0318* |
| Venous invasion (− vs +) | 0.3366 (0.0796‐0.9727) | .0437* | 0.3776 (0.0843‐1.2222) | .1090 |
| Perineural invasion (− vs +) | 0.3405 (0.1538‐0.7864) | .0129* | 0.7228 (0.2996‐1.7867) | .4742 |
| HLA class I (low vs high) | 1.6634 (0.7644‐3.8001) | .2011 | — | — |
| HLA class II (low vs high) | 1.1777 (0.5421‐2.5977) | .6782 | — | — |
| tPD‐L1 (low vs high) | 0.5936 (0.2626‐1.3081) | .1949 | — | — |
| sPD‐L1 (low vs high) | 2.5843 (1.1600‐6.3016) | .0196* | 1.7512 (0.6893‐4.6548) | .2393 |
| PD‐1 (low vs high) | 2.1281 (0.9656‐5.0206) | .0612 | — | — |
| CTLA‐4 (low vs high) | 1.7347 (0.7948‐3.9707) | .1676 | — | — |
| CD3 (low vs high) | 2.2688 (1.0144‐5.5475) | .0460* | 2.3560 (0.9905‐6.0541) | .0526 |
| CD4 (low vs high) | 1.5236 (0.6964‐3.4939) | .2941 | — | — |
| CD8 (low vs high) | 1.6338 (0.7483‐3.7475) | .2197 | — | — |
| TIA‐1 (low vs high) | 1.1064 (0.5106‐2.4350) | .7970 | — | — |
| T‐bet (low vs high) | 1.0622 (0.4836‐2.3383) | .8792 | — | — |
| GATA3 (low vs high) | 1.0641 (0.4911‐2.3413) | .8745 | — | — |
| Foxp3 (low vs high) | 1.4531 (0.6679‐3.2590) | .3464 | — | — |
| RorγT (low vs high) | 1.5666 (0.7171‐3.5898) | .2623 | — | — |
| CD163 (low vs high) | 1.2735 (0.5856‐2.8553) | .5428 | — | — |
Abbreviations: CI, confidence interval; F, female; HR, hazard ratio; M, male; mod, moderate; PD‐1, programmed cell death‐1; sPD‐L1, programmed cell death‐ligand 1 in stromal cells; tPD‐L1, programmed cell death‐ligand 1 in tumor cells.
*
P < .05